Rationale-Cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger which, upon b-adrenergic receptor (b-AR) stimulation, acts in microdomains to regulate cardiac excitation-contraction coupling by activating the cAMP-dependent protein kinase (PKA) phosphorylation of calcium handling proteins. One crucial microdomain is in vicinity of the cardiac ryanodine receptor type 2 (RyR2) which is associated with arrhythmogenic diastolic calcium leak from the sarcoplasmic reticulum (SR) often occurring upon RyR2 hyperphosphorylation by PKA and calcium/calmodulin-dependent kinase.
Introduction
b-Adrenergic receptors (b-ARs) regulate cardiac excitation-contraction coupling by stimulation of the second messenger 3',5'-cyclic adenosine monophosphate (cAMP) synthesis and downstream phosphorylation of several calcium handling proteins by the cAMP-dependent protein kinase (PKA). These include L-type calcium channels responsible for calcium influx upon depolarization in the T-tubular membrane invaginations, cardiac ryanodine receptors type 2 (RyR2s) responsible for calcium-induced calcium release from the sarcoplasmic reticulum (SR), and activation of the SR calcium ATPase (SERCA2a) via phospholamban phosphorylation. 1, 2 Individually, each of these calcium handling proteins exists as a macromolecular complex comprised of A-kinase anchoring proteins, PKA, phosphatases, cAMP degrading enzymes phosphodiesterases (PDEs) and additional components, in concert enabling differentially regulated subcellular cAMP microdomains. [3] [4] [5] [6] Under physiological conditions, these microdomains tightly regulate calcium cycling and finetune the classical "fight-or-flight" response. In contrast, cardiac diseases such as heart failure lead to significant molecular remodeling of the signaling complexes and alterations in microdomain-specific cAMP dynamics. 4, 7 For example, in the healthy heart, RyR2 channels are usually closed in diastole and stabilized by allosteric interactions with the small regulatory protein calstabin2 (also called FKBP12.6) 8 and PDE4, which lowers cAMP in the vicinity of RyR2 and limits PKA-dependent phosphorylation in a negative feedback loop. 9 In heart failure, however, calstabin2 and PDE4 are decreased in the RyR2 complex, leading to hyperphosphorylation of RyR2 and increased diastolic calcium leak, increasing the susceptibility for life-threatening arrhythmias. 9, 10 In addition, RyR2 is phosphorylated by the calcium-calmodulin dependent protein kinase II (CaMKII) downstream of b1-AR subtype, which also increases calcium leak due to RyR2 hyperphosphorylation 11 e.g. via the exchange protein directly activated by cAMP (Epac). 12, 13 Although these disease-associated, chronic molecular changes have been well established, 14 direct microdomain-specific monitoring of cAMP in the vicinity of RyR2 with high spatial and temporal resolution which could allow detection of early disease-relevant mechanisms, was so far not possible due to a lack of appropriate imaging techniques.
Here, we designed the first targeted cAMP biosensor, which can be used to directly monitor local cAMP dynamics in the RyR2 microdomain. Using this sensor in transgenic mice subjected to an in vivo hypertrophy model of early cardiac disease, we could observe dramatic pathology-associated changes in the microdomain-specific cAMP levels.
Furthermore, there were functionally relevant changes in local cAMP degradation presumably due to subcellular redistribution of PDE2, 3 and 4 isoforms. Therefore, our novel targeted fluorescence biosensor and the respective transgenic mouse model should be useful for understanding real time cAMP dynamics at the cardiac RyR2 under normal and pathological conditions.
Results

Generation of a new RyR2-targeted biosensor transgenic mouse model
To monitor cAMP dynamics locally in the vicinity of RyR2, we sought to target the FRETbased cAMP biosensor Epac1-camps to the macromolecular complex of the calcium release unit without affecting cardiac function. Fusing the biosensor to the cytoplasmic N-terminus of junctin (JNC), a transmembrane SR protein which forms a stable complex with RyR2, resulted in a new targeted cAMP sensor termed Epac1-JNC. Next, we generated transgenic mice that express this new biosensor in adult myocardium under the control of α-myosin heavy chain promoter (Fig. 1A) . Confocal microscopy of transgenic adult mouse ventricular cardiomyocytes immunostained with RyR2 antibody revealed proper co-localization of the biosensor with subcellular calcium release units (Fig. 1B) . Importantly, this targeted biosensor could be co-immunoprecipitated with RyR2 ( Supplementary Fig. 1 ), and live cell FRET imaging in isolated adult ventricular myocytes showed a rapid FRET response to the beta-adrenergic agonist isoproterenol (ISO), indicating cAMP synthesis and accumulation at RyR2 clusters (Fig. 1C) .
Epac1-JNC mice had normal life expectancy and did not show any phenotypic abnormalities.
The heart and left ventricular weights divided by body mass or tibia length, respectively, were comparable to wildtype littermates ( Supplementary Fig. 2A ,B) as were the morphology of cardiac cross-sections and cardiomyocyte size ( Supplementary Fig. 2C,D ).
Echocardiography at 6 months of age showed no signs of ventricular dilation or impairment of contractile function. There were no significant differences in heart dimensions compared to wildtype littermates apart from a slight increase of diastolic but not systolic anterior and posterior wall thicknesses (Supplementary Table 1) . Notably, this contrasts with the previously described pronounced hypertrophy phenotype in transgenic mice overexpressing canine junctin >10-30 fold. 15, 16 In our model, based on qPCR, junctin overexpression was less than 30-fold ( Supplementary Fig. 2E) Fig. 2A-C) . This suggests that either the number of β2-ARs is insufficient in these cells 19 or cAMP synthesis activated by β2-AR in Ttubular invaginations 20 near RyR2 clusters does not cross the dyadic cleft to reach the RyR2 microdomain. In sharp contrast, TAC myocytes showed a clear increase of local cAMP directly in the RyR2 microdomain after β2-AR stimulation (Fig. 2D) . In contrast to the lack of changes observed post-TAC for β1-AR stimulation, β2-AR stimulation induced a pronounced cAMP response in the RyR2 microdomain (Fig. 2E) . To study the responsible molecular mechanisms, we next analyzed the effects of different PDE isoforms expressed in the heart.
Differential PDE regulation of the RyR2 microdomain
To understand how local cAMP levels are controlled in the RyR2 microdomain compared to the bulk cytosol, we isolated cardiomyocytes either from untreated Epac1-JNC or Epac1-camps transgenic mice 21 and stimulated them with a subsaturating concentration of ISO (3 nmol/L) followed by selective inhibition of PDE2, 3 or 4 subfamilies. Interestingly, while PDE2 inhibition did not influence cAMP signaling in the RyR2 microdomain (Fig. 3A,B ) and the PDE3 inhibitor effect was relatively small, the PDE4 inhibitor rolipram produced a very strong local signal increase in the RyR2 microdomain (Fig. 3C) . Of note, the actual cAMP affinity of the Epac1-JNC sensor measured using a cell permeable cAMP analogue was comparable with that of the cytosolic sensor Epac1-camps (Supplementary Fig. 3 ). On average, the PDE4-dependent signal was 2-3-fold stronger in the RyR2 microdomain compared to the cytosol ( Fig. 3C-E) . This supports the concept that PDE4 anchored directly to the RyR2 complex represents the major cAMP-degrading activity involved in the local regulation of RyR2 microdomains.
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Microdomain specific effects of PDEs are significantly changed in early heart disease
To analyze whether the local β-AR/cAMP signal changes observed after TAC might originate from PDE changes in the RyR2 microdomain, we performed FRET measurements comparing sham and TAC transgenic Epac1-JNC cells. Cardiac remodeling post-TAC led to a significant increase of PDE2, but a smaller increase of PDE3 inhibitor effect in the RyR2 microdomain ( Fig. 4A ,B,E). Strikingly, while the dominant PDE4 contribution was confirmed for sham cells, cAMP synthesis was dramatically blunted after TAC in the RyR2 microdomain ( Fig. 4C-E) . However, whole-cell expression levels of all three PDEs detected by immunoblotting were not altered at this early stage of disease ( Supplementary Fig. 4 ). This strongly suggests that TAC leads to local alterations of PDE activities in the RyR2 microdomain, especially to a local depletion of PDE4, which were previously not detectable using classical biochemical techniques, somewhat similar to previously observed PDE redistribution in subsarcolemmal microdomains. 4 To further support the notion that PDE4 may locally restrict microdomain access of β2-AR/cAMP to RyR2, we pre-blocked PDE4 selectively in healthy cells with 10 µM rolipram and stimulated β2-AR as described above (see Fig 2C- This was accompanied by faster cell shortening, as confirmed by β1-AR stimulation of sham cells ( Supplementary Fig. 5E ). These data strongly suggest that a PDE redistribution post-TAC augments β2-AR/cAMP levels in the RyR2 microdomain while SR calcium loading via SERCA2a is accelerated.
To assess if the increased calcium leak and faster calcium loading in post-TAC cardiomyocytes lead to increased arrhythmia susceptibility, we imaged calcium waves following β2-AR stimulation under steady-state conditions immediately following 1Hz pacing.
While untreated post-TAC cardiomyocytes typically showed no calcium waves similar to sham, β2-AR stimulation induced a significant increase in calcium waves only in post-TAC but not in sham cells (Fig. 5C) . Furthermore, ISO stimulation resulted in a profound increase in calcium waves in the same sham cells that showed no significant effect to β2-AR selective stimulation (Fig. 5C) Fig. 6 ).
Discussion
In this work, we designed a novel microdomain-specific, targeted FRET biosensor and generated the first transgenic mouse model to measure real time cAMP dynamics in the direct vicinity of cardiac RyR2 channels. To target the highly sensitive cytosolic Epac1-camps sensor to this important microdomain, we sought to obtain a localized fusion protein, which forms a stable macromolecular complex with RyR2. Since the size of calcium release channel itself (megadalton range) makes a fusion protein strategy difficult, an essential RyR2 interacting protein may serve as targeting candidate. However, one possible protein with high-affinity interactions, calstabin2 (FKBP12.6), previously used to target a calcium sensor to the diadic cleft, 22 was shown to dissociate from RyR2 upon β-adrenergic stimulation 23 investigated here. Therefore, we used the mouse junctin homologue as interaction partner to target the RyR2 complex 24 through a fusion protein strategy with Epac1-camps. The new RyR2-targeted biosensor Epac1-JNC (see Fig. 1A ) showed excellent co-localization with RyR2 in adult cardiomyocytes and generated robust FRET responses, which were clearly different from those measured in the cytosol (see Figs. 2 and 3 ). This suggests that the novel targeted biosensor can specifically report local cAMP dynamics in the RyR2 microdomain. Importantly, biosensor affinity for cAMP was comparable with that of the parental cytosolic construct (Supplementary Fig. 3 ), indicating that local versus global cAMP responses can be roughly compared between the respective mouse strains.
Since overexpression of a canine JNC isoform in transgenic mice led to marked cardiac hypertrophy, 15, 16 we thoroughly investigated whether Epac1-JNC mice might have any adverse phenotype. Up to the age of 6 months, there were no changes in cardiomyocyte size, cardiac morphometric or echocardiographic parameters, apart from a slight increase of posterior but not anterior diastolic wall thickness (see Supplementary Fig. 2 and and also to that previously described in Epac1-camps mice which underwent the same procedure. 5 Here, the transcript level of mouse JNC expression in Epac1-JNC mice was less than 30-fold times control, which is comparable with the previously described canine JNC transgenic models (Supplementary Fig. 2E ).
Supplementary
15, 16
Surprisingly, β2-AR, which was previously located in the T-tubules of rat ventricular myocytes where it generates highly compartmentalized second messenger signals 20 , did not produce any increase in local RyR2-associated cAMP levels in healthy mouse cells (see Fig. 2 ). This suggests that either the expression of this receptor is too low in mouse ventricular cardiomyocytes, as recently demonstrated, 19 or the cAMP generated after β2-AR activation does not cross the 10-15 nm wide diadic cleft, presumably due to high degree of compartmentalized PDE-mediated cAMP degradation. Subsequent FRET measurements have identified PDE4 as the major PDE type responsible for cAMP hydrolysis in the vicinity of RyR2, while the participation of PDE3 was much less pronounced and that of PDE2 was undetectable in this microdomain (see Fig. 3 ). This is in line with a previous report, which identified PDE4D3 as a direct interaction partner with cAMP hydrolyzing activity in the RyR2 macromolecular complex. 9 To study the pathological changes of local cAMP dynamics, we focused on a relatively early, often latent cardiac disease state of hypertrophy, because it is significantly less well understood than the chronic and advanced pathology of terminal heart failure. To this end, we used a highly reproducible TAC intervention in the FVB/N1 mouse heart, which has been Figure 4) . Instead, we were able to uncover a PDE redistribution in or between subcellular microdomains. Previously, we have shown that TAC leads to a redistribution of PDE2 from β1-AR to β2-AR-associated plasma membrane compartments, while PDE3 activity was specifically reduced at the β2-AR with a so far unknown relocation destiny. 4 In this work, we show that both PDE2 and PDE3 effects are increased at the RyR2 microdomain after TAC (see Fig. 4 ). This suggests that in hypertrophy, PDE3 might redistribute across the cleft from β2-AR located at the T-tubular membrane to the junctional SR where RyR2 is found. However, the most prominent diseaseassociated alteration in the RyR2 microdomain is the dramatic loss of PDE4 activity (see cAMP at RyR2 could be linked to a significant increase in calcium spark generation and a strong tendency towards increased ventricular arrhythmias (Fig. 5B, Supplementary Fig. 6 ).
Importantly, β2-AR stimulation triggered calcium waves in TAC but not in sham cells, overall similar to the calcium overload effects associated with β1-AR stimulation, which was confirmed in sham cells (see Fig. 5 ). This occurs in concert with a moderate increase of cell contractility and relaxation (see Supplementary Figure 5 ) and might serve as an important pathological mechanism of increased arrhythmia susceptibility in response to normally cardioprotective 25, 26 β2-AR subtype stimulation.
In conclusion, we have generated a novel FRET-based biosensor and a corresponding transgenic mouse model which can be used to directly monitor local cAMP dynamics in the vicinity of cardiac RyR2. While our experimental data obtained using this system represent only the first step towards understanding local cAMP changes in an early cardiac disease model, this technique clearly demonstrates dramatic alterations of local PDE effects, which might explain significant changes in microdomain specific cAMP levels and increased susceptibility for ventricular arrhythmias. In the future, this real time method can be used to better dissect molecular mechanisms of altered RyR2 function in various cardiac pathologies for the development of new RyR2-targeted therapies aimed at counteracting the detrimental microdomain remodeling. 
Methods
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Generation of transgenic mice. The α-MHC-based vector containing Epac1-JNC sequence was linearized using SpeI, purified and used for pronuclear injections. 29 Founder mice and their heterozygote offspring were genotyped by PCR using the following primers:
TGACAGACAGATCCCTCCTAT and CATGGCGGACTTGAAGAAGT, giving a ~340 bp fragment on a gel. Positive founder mice were bred with wildtype FVB/NRj animals (Janvier Labs, Saint Berthevin, France) to generate a heterozygous offspring line.
Cardiomyocyte isolation and FRET measurements. Adult ventricular cardiomyocytes
were isolated by enzymatic digestion during Langendorff perfusion, plated on laminin coated round glass coverslides and used for FRET or Ca 2+ measurements as previously described.
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Transverse aortic constriction (TAC). All animal experiments were performed in accordance with institutional (Tierschutzbüro Universitätsmedizin Göttingen) and governmental (LAVES Niedersachsen, BGV Hamburg) guidelines. Female mice aged 8-12
weeks were randomized into sham or TAC groups and anesthetized using 2% isoflurane in pure oxygen. A suprasternal incision was made, and the aortic arch was visualized using a binocular operating stereoscope (Olympus). TAC interventions used a spacer-defined (26-gauge) constriction fixed by a 6-0 polyviolene suture between the first and second trunk of the aortic arch. 32 For sham, the aorta was exposed as for TAC but not constricted. Line scans were performed at ~2,45 ms time intervals with a 0.1 µm pixels size and applied longitudinally to the cell axis to access the cell length. Data were expressed as ΔF/F0, where F is the fluorescence intensity, and F0 is the intensity at rest. Myocytes were stimulated 5x at 1 Hz via platinum electrodes (5ms, 20V) connected to an IonOptics stimulator (Westwood, MA 02090). Experiments were stopped if the investigated myocyte showed Ca 2+ waves in control conditions. Ca 2+ sparks were analyzed after field stimulation by sparkmaster as previously described.
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Statistics. Echocardiographic, morphometric, real time PCR and FRET data were analyzed using the Origin Pro 8.5 software (OriginLab Corporation, Northhampton, MA). Normal distribution was tested by the Kolmogorov-Smirnov test, and differences between the groups were analyzed using mixed ANOVA followed by Wald Chi-squared test, one-way ANOVA for In the RyR2 microdomain, we could detect virtually no effect of the PDE2 inhibitor, while PDE4 contribution was significantly higher than in the bulk cytosol.
(E) Quantification of the FRET experiments shown in A-D and similar experiments performed using the PDE3 inhibitor cilostamide (10 µmol/L). Means ± SE, number of hearts/cells is indicated above the bars. * -significant differences at p<0.05, mixed ANOVA followed by Wald c 2 test. In healthy cardiomyocytes, β 1 -but not β 2 -AR-cAMP pools stimulate the RyR2 microdomain because of low β 2 -AR expression and/or tight PDE-mediated control of β 2 -AR/cAMP in the dyadic cleft (B) already in early cardiac disease, characterized by hypertrophy but before the onset of chronic heart failure, the RyR2-associated PDE4 effects are lost, which is incompletely compensated by increased local PDE2 and PDE3 contributions. Overall, this might lead to augmented β 2 -AR/cAMP signals at RyR2 channels and increased calcium wave generation in line with increased arrhythmia susceptibility from hypertrophic remodeling.
